Daniel James George, MD

Professor of Medicine
Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-4615
Email address daniel.george@duke.edu

Education and Training

  • Fellow in Medical Oncology, Medicine, Johns Hopkins University, 1995 - 1998
  • Medical Resident, Medicine, Johns Hopkins University, 1992 - 1995
  • M.D., Duke University, 1992

Grants

Publications

Armstrong, Andrew J., Santosh Gupta, Patrick Healy, Gabor Kemeny, Beth Leith, Michael R. Zalutsky, Charles Spritzer, et al. “Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.” Plos One 14, no. 5 (2019): e0216934. https://doi.org/10.1371/journal.pone.0216934.

PMID
31136607
Full Text

Staehler, Michael, Dena Battle, Axel Bex, Hans Hammers, and Daniel George. “Re: Sunitinib Alone or after Nephrectomy in Metastatic Renal-cell Carcinoma.” Eur Urol 74, no. 6 (December 2018): 842–43. https://doi.org/10.1016/j.eururo.2018.08.011.

PMID
30170873
Full Text

Zhang, Tian, Andrew J. Armstrong, Daniel J. George, and Jiaoti Huang. “The promise of immunotherapy in genitourinary malignancies.” Precis Clin Med 1, no. 3 (December 2018): 97–101. https://doi.org/10.1093/pcmedi/pby018.

PMID
30687563
Full Text

Choueiri, Toni K., Colin Hessel, Susan Halabi, Ben Sanford, M Dror Michaelson, Olwen Hahn, Meghara Walsh, et al. “Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125].” Eur J Cancer 103 (November 2018): 287. https://doi.org/10.1016/j.ejca.2018.09.022.

PMID
30270112
Full Text

Staehler, M., R. J. Motzer, D. J. George, H. S. Pandha, F. Donskov, B. Escudier, A. J. Pantuck, et al. “Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.” Ann Oncol 29, no. 10 (October 1, 2018): 2098–2104. https://doi.org/10.1093/annonc/mdy329.

PMID
30412222
Full Text

Gao, Xin, Opeyemi Jegede, Connor Gray, Paul J. Catalano, Jesse Novak, David J. Kwiatkowski, Rana R. McKay, et al. “Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.” Clin Genitourin Cancer 16, no. 5 (October 2018): 341–48. https://doi.org/10.1016/j.clgc.2018.04.001.

PMID
29754934
Full Text

Choueiri, T. K., A. Flaifel, W. Xie, D. Braun, M. Ficial, R. Jennings, A. Nassar, et al. “PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials.” In Ann Oncol, 29 Suppl 8:viii726, 2018. https://doi.org/10.1093/annonc/mdy424.040.

PMID
32138002
Full Text

Harrison, M. R., P. G. Davis, M. G. Khouri, R. T. Gupta, A. J. Armstrong, M. A. McNamara, T. Zhang, et al. “EXTEND: Safety and efficacy of exercise training in men receiving enzalutamide (ENZ) in combination with conventional androgen deprivation therapy (ADT) for hormone naïve prostate cancer (HSPC).” In Ann Oncol, 29 Suppl 8:viii623–24, 2018. https://doi.org/10.1093/annonc/mdy300.064.

PMID
32137677
Full Text

George, D. J., A. J. Pantuck, R. Figlin, B. Escudier, S. Halabi, M. Casey, X. Lin, L. Serfass, M. J. Lechuga Frean, and A. Ravaud. “Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial.” In Ann Oncol, 29 Suppl 8:viii312, 2018. https://doi.org/10.1093/annonc/mdy283.090.

PMID
32136726
Full Text

Pages